The Hematology/Oncology Pharmacy Association (HOPA), alongside the Coalition to Improve Access to Cancer Care (CIACC), voices its support for the recent reintroduction of the Cancer Drug Parity Act.
The legislation - reintroduced to Congress on June 24, 2025, by Representatives Glenn Grothman (WI-06), Suzanne Bonamici (D-OR), Gus Bilirakis (R-FL), Joe Morelle (D-NY), Brian Fitzpatrick (R-PA), and Doris Matsui (D-CA) - would require group and individual health insurance plans to cover oral and self-administered anticancer medications at a cost no less favorable than the cost of IV, port-administered, or injected anticancer medications. By removing the imbalance in insurance coverage, the Cancer Drug Parity Act would help make oral and self-administered cancer treatments less expensive and more accessible.
HOPA President Robert Mancini, PharmD, BCOP, FHOPA, added the association's support for the reintroduced legislation in a recent CIACC press release.
"As providers, we have seen tremendous progress in cancer treatments, and the Cancer Drug Parity Act would protect patients' access to the treatments their oncologists prescribe," Mancini noted, in the release. "By ensuring that patient cost sharing for oral anticancer drugs is no less favorable than for IV chemotherapy, this bill would help remove one financial barrier to care and ensure patients get the right treatment."
To read the entire CIACC press release applauding the reintroduction of the Cancer Drug Parity Act, click here - and click here to read the text of the house bill itself. And to get involved and help advocate for the Cancer Drug Parity Act and other issues important to HOPA and optimized cancer care, visit HOPA's Legislative Action Center.
